elbasvir (MK-8742) / Merck (MSD) - LARVOL DELTA

Third Time's the Charm: Virologic Suppression After 2 Consecutive DAA Failures in Chronic Hepatitis C (ACG 2026) - "Introduction: Direct-acting antivirals achieve sustained virologic response (SVR) in over 95% of patients with chronic hepatitis C virus (HCV) infection, so sequential failure of multiple regimens is rare, and evidence guiding retreatment after sofosbuvir/velpatasvir/voxilaprevir failure is limited and extrapolated from small studies.[1] We present a non-cirrhotic genotype 1a patient with an NS5A L31M resistance-associated variant (RAV) who failed two sequential regimens but achieved on-treatment suppression with an extended course plus ribavirin...L31M was classified as conferring possible resistance to daclatasvir, elbasvir, ledipasvir, and ombitasvir, but no determinable impact on velpatasvir or pibrentasvir...Third, the recommendation for this extended regimen after voxilaprevir failure rests on a retrospective study of only four patients, so each real-world case adds to a thin evidence base. Suppression after two failed courses suggests extended duration and..."

Cardiovascular • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Orthopedics • Portal Hypertension

hnRNPC facilitates coronavirus replication by directly binding the frameshift-stimulatory element of viral genomic RNA. (PubMed, PLoS Pathog) - "Finally, we demonstrated that the small molecule Elbasvir directly binds hnRNPC, disrupting the interaction between hnRNPC and FSE RNA and inhibiting coronavirus replication by decreasing -1 PRF efficiency. Collectively, our study identifies hnRNPC as a key host cofactor for coronaviruses and provides a novel target for broad-spectrum antiviral drug development."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • HNRNPC

Elbasvir Inhibits Hepatitis E Virus Internalization and, in Combination with Ribavirin, Achieves Sustained Viral Suppression In Vitro. (PubMed, Pathogens) - "Furthermore, combination with ribavirin enhanced antiviral efficacy, resulting in sustained viral suppression without detectable cytotoxicity and exhibiting an additive interaction. Collectively, these findings identify elbasvir as a promising candidate for repurposing as an anti-HEV drug and support a combination strategy targeting distinct steps of the viral life cycle."

Journal • Preclinical • Hepatitis C • Infectious Disease • Inflammation

Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus. (PubMed, North Clin Istanb) - "This study provides compelling in silico evidence that drug repurposing of clinically approved antiviral agents may accelerate the development of effective HMPV-specific therapies. By targeting the highly conserved and functionally critical HMPV F protein, the identified candidate compounds offer strong translational potential and justify prioritization for experimental validation and preclinical investigation. Collectively, these results contribute to filling a critical therapeutic gap and support drug repurposing as a viable and time-efficient strategy to address emerging and neglected viral respiratory infections."

Journal • Hepatitis C • Infectious Disease • Inflammation • Respiratory Diseases

The lncRNA DAMER selectively guides m6A-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer. (PubMed, Nat Cell Biol) - "Elbasvir dismantles this adaptive programme, targeting tumour asparagine dependency and exhibiting potent antitumour effects in preclinical models. Our findings reveal a paradigm for lncRNA-guided RNA demethylation that solves a target specificity enigma and offers a strategy targeting metabolic adaptation in cancer."

Journal • Oncology • ALKBH5 • ATF4

Elbasvir triggers ferroptosis in esophageal squamous cell carcinoma through NCOA4-mediated ferritinophagy. (PubMed, Med Oncol) - "Elbasvir targets NCOA4-FTH1 to induce ferroptosis, offering a repurpose strategy for ESCC. Its safety profile supports clinical translation, with potential applications in iron metabolism-dependent cancers."

Journal • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • NCOA4

LDHC4 promotes ovarian cancer progression through H4K12 lactylation to regulate PGK1 expression and modulate glycolysis. (PubMed, J Transl Med) - No abstract available

Journal • Oncology • Ovarian Cancer • Solid Tumor • PGK1

In silico screening of potential FGF2 inhibitors for cancer therapy. (PubMed, In Silico Pharmacol) - "Molecular docking study showed Elbasvir (1) to exhibit the strongest binding affinity (-8.1 kcal/mol), followed by Velpatasvir (2) (-7.6 kcal/mol), Daclatasvir (3) (-7.5 kcal/mol), Ritonavir (4) (-6.2 kcal/mol), Paliperidone Palmitate (5) (-5.9 kcal/mol), Saralasin (6) (-5.4 kcal/mol), Nystatin (8) (-5.2 kcal/mol), and Cobicistat (-5.1 kcal/mol)...Overall, the study provides mechanistic insights into the molecular interactions between FGF2 and these candidate drugs, highlighting the promising potential of compounds 1-6 and 8 for subsequent in vitro validation in cancer therapeutics. The online version contains supplementary material available at 10.1007/s40203-025-00495-2."

Journal • Acute Myelogenous Leukemia • Brain Cancer • Breast Cancer • Gastric Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • FGF2 • FGFR

Targeting Telomere Shelterin Protein TPP1 with Elbasvir: Induction of Autophagy and Suppression of Esophageal Cancer Tumorigenesis. (PubMed, Anticancer Agents Med Chem) - "TPP1 emerges as a compelling diagnostic indicator and a potential treatment focus in esophageal cancer, with Elbasvir offering promise as a novel therapeutic agent."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • TPP1

Potential Inhibitors of SARS-CoV-2 Developed through Machine Learning, Molecular Docking, and MD Simulation. (PubMed, Med Chem) - "The results emphasize the efficacy of integrating molecular docking, machine learning, and molecular dynamics simulations in facilitating the rapid identification of novel inhibitors. PubChem ID: 23658468 demonstrates robust binding affinity to ACE2 and favorable pharmacokinetic properties, establishing it as a promising candidate for further investigation."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Structural insight into the conversion of DhNik1, a hybrid histidine kinase from Debaryomyces hansenii to a cytotoxic phosphatase conformation for novel antifungal agent. (PubMed, J Mol Biol) - "The structure of DhNik1CT was used for virtual screening to identify a small molecule which modulates the activity of DhNik1 towards cytotoxicity. Taken together, present study shows that the conversion of HHK3 to a toxic conformation by a small molecule is a feasible approach for discovering novel antifungal drug."

Journal

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. (PubMed, BMJ Open Gastroenterol) - "The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Exploring bacterial key genes and therapeutic agents for breast cancer among the Ghanaian female population: Insights from In Silico analyses. (PubMed, PLoS One) - "Subsequently, the bKG-guided top ranked 10 drug molecules Digitoxin, Digoxin, Ledipasvir, Suramin, Ergotamine, Venetoclax, Nilotinib, Conivaptan, Dihydroergotamine, and Elbasvir were identified using molecular docking analysis. The stability of top-ranked three drug-target complexes (Digitoxin-pykA, Digoxin-mdh, and Ledipasvir-pgi) were confirmed through the molecular dynamics simulation studies. Therefore, these findings might be useful resources to the wet-lab researchers for further experimental validation on bacterial therapies against BC."

Journal • Breast Cancer • Infectious Disease • Oncology • Solid Tumor

Drugs for hepatitis C virus infection. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Addiction (Opioid and Alcohol) • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Table 3: Some drug interactions with DAAs for HCV infection. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Figure 1: Treatment of hepatitis C virus infection in treatment-naive adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors. (PubMed, Sci Rep) - "Compared with the WT, the Q24K/L28M/R30Q/A92K RASs was 36,000-fold resistant to daclatasvir, 440,000-fold resistant to ledipasvir, 6300-fold resistant to velpatasvir, 3100-fold resistant to elbasvir, and 1.8-fold resistant to pibrentasvir. Furthermore, a combination of pibrentasvir and sofosbuvir showed therapeutic efficacy against these RASs. Combination regimens may eradicate HCV with NS5A Q24K/L28M/R30E/A92K RASs."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC. (PubMed, Int Immunopharmacol) - "Following, virtual screening and redocking analysis, Elbasvir, Ledipasvir, and Lomitapide drugs for EGFR mutants (>-10.8 kcal/mol) while Indinavir, Ledipasvir, Lomitapide, Monteleukast, and Isavuconazonium for ROS1 mutants (>-8.8 kcal/mol) were found as putative inhibitors. Furthermore, classical molecular dynamics simulation and endpoint binding energy calculation support the considerable stability of the selected docked complexes aided by substantial hydrogen bonding and hydrophobic interactions in comparison to the respective control complexes. Conclusively, the repositioned FDA-approved drugs might be beneficial alone or in synergy to overcome acquired resistance to EGFR and ROS1-positive lung cancers."

Journal • Tumor mutational burden • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • ROS1 • TMB

Discovery of Bacterial Key Genes from 16S rRNA-Seq Profiles That Are Associated with the Complications of SARS-CoV-2 Infections and Provide Therapeutic Indications. (PubMed, Pharmaceuticals (Basel)) - "Then, we detected bKG-guided top-ranked eight drug molecules (Bemcentinib, Ledipasvir, Velpatasvir, Tirilazad, Acetyldigitoxin, Entreatinib, Digitoxin, and Elbasvir) by molecular docking. Finally, the binding stability of the top-ranked three drug molecules (Bemcentinib, Ledipasvir, and Velpatasvir) against three receptors (hldD, mlaA, and lptD) was investigated by computing their binding free energies with molecular dynamic (MD) simulation-based MM-PBSA techniques, respectively, and was found to be stable. Therefore, the findings of this study could be useful resources for developing a proper treatment plan against bacterial co-/super-/secondary-infection in SARS-CoV-2 infections."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes. (PubMed, Sci Rep) - "We focused on HSPE1, which was designated as the hub gene due to its paramount importance in the SVM model, and computed the docking structures for four compounds: ZINC3978005 (Dihydroergotamine), ZINC52955754 (Ergotamine), ZINC150588351 (Elbasvir), and ZINC242548690 (Digoxin). Our study identified two subtypes of LUAD patients based on oxidative stress and immunotherapy-related genes. Our findings provided subtype-specific therapeutic strategies."

IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AURKA • BIRC5 • GSTP1 • HSPD1 • NDUFS1

Voyage into uncharted chemical space in drug discovery (ACS-Fall 2023) - "However, only a small fraction of these fit in the Lipinski's Rule of Five which was previously believed to be suitable for small molecule oral drug synthesis. In this presentation, we will discuss the synthetic strategies that enabled us to venture beyond Rule of Five chemical space to discover the NS5A inhibitors Elbasvir and Ruzasvir for the treatment of HCV."

In silico Antivirus Repurposing and its Modification to Organoselenium Compounds as SARS-CoV-2 Spike Inhibitors. (PubMed, Pak J Biol Sci) - "The best-modified ligand was chosen by analyzing the ADME-Tox property, RMSD value and binding energy value. <b></b> The best three unmodified ligands, Ombitasvir, Elbasvir and Ledipasvir, have a binding energy value of -15.8065, -15.3842 and -15.1255 kcal mol¹, respectively and the best three modified ligands ModL1, ModL2 and ModL3 has a binding value of -15.6716, -13.9489 and -13.2951 kcal mol¹, respectively with an RMSD value of 1.7109 Å, 2.3179 Å and 1.7836 Å."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an in silico drug discovery study. (PubMed, J Biomol Struct Dyn) - "The pharmacokinetic properties of the identified drugs were predicted and demonstrated good ADMET characteristics. Overall, these results indicated that valspodar, dactinomycin, elbasvir, temsirolimus, and sirolimus hold promise as prospective P-gp inhibitors and warrant further invitro/invivo investigations."

Journal • Oncology • ABCB1

In-silico docking studies of selected phytochemicals against papain like protease of SARS-Cov-2. (PubMed, Vegetos) - "Phytochemicals such as Tinosponone, Rhoifolin, Rosmanol, Berberin, Nimbin and two other existing drugs Elbasvir and Declatasvir showed higher inhibitory potential in terms of higher binding affinities...Molecular Dynamics simulation of Tinosponone with PLpro has proved the stability and validity of the binding with RMSD value in range of 0.2 nm when it was run for 50 ns using GROMACS. Therefore, Tinosponone could be considered as a potential inhibitor of PLpro of SARS CoV-2."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Evaluations of FDA-approved drugs targeting 3CLP of SARS-CoV-2 employing a repurposing strategy. (PubMed, Comb Chem High Throughput Screen) - "The aim of this article was to explore the FDA approved drugs as repurposing study against 3CLP for COVID-19 management."

FDA event • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases